| Name | Title | Contact Details |
|---|---|---|
Brian Lefort |
Chief Human Resources Officer | Profile |
Nina Laven |
Chief Human Resources Officer | Profile |
Pralay Senchaudhuri |
Vice President, Product Development | Profile |
Steve Herbert |
Vice President Sales and Business Development | Profile |
Steve Herbert |
VP Sales/Business Development | Profile |
4D Pharmacy Management Systems Inc is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
WCG is the world`s largest and most trusted provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG`s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials. WCG is proud to serve the individuals on the frontlines of science and medicine, and the organizations that strive to develop new products and therapies to improve the quality of human health. It is our role to empower them to accelerate advancement, while ensuring that the risks of progress never outweigh the value of human life.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.